Citations

Clear

367 citation(s) found for "Su, Pan".

FOXO1 Inhibits Runx2 Transcriptional Activity and Prostate Cancer Cell Migration and Invasion
Zhang, Haijun , Pan, Yunqian , Choe, Chungyoul , Lindgren, Bruce R. , Jensen, Eric D. , Westendorf, Jennifer J., Cheng, Liang , Zheng, Li Wu , Huang, Haojie , Cheng, Liang

Mayo Clinic

Cancer Research | April 20, 2011 | Volume: 71 | Issue: 9 | Pages: 3257-3267

10.1158/0008-5472.can-10-2603 | PMID 21505104 Get It

Abstract Prostate cancer patients with regional lymph node involvement at radical prostatectomy often experience disease progression to other organs, with the bone as the predominant site. The transcription factor Runx2 plays an important role in bone formation and prostate cancer cell migration, invasion, and metastasis. Here we showed that the forkhead box O (FOXO1) protein, a key downstream effector of the tumor suppressor PTEN, inhibits the transcriptional activity of Runx2 in prostate cancer cells. This inhibition was enhanced by PTEN but diminished by active Akt. FOXO1 bound to Runx2 in vitro and in vivo and suppressed Runx2's activity independent of its transcriptional function. FOXO1 inhibited Runx2-promoted migration of prostate cancer cells, whereas silencing of endogenous FOXO1 enhanced prostate cancer cell migration in a Runx2-dependent manner. Forced expression of FOXO1 also inhibited Runx2-promoted prostate cancer cell invasion. Finally, we found that expression of PTEN and the level of FOXO1 in the nucleus is inversely correlated with expression of Runx2 in a cohort of prostate cancer specimens from patients with lymph node and bone metastasis. These data reveal FOXO1 as a critical negative regulator of Runx2 in prostate cancer cells. Inactivation of FOXO1 due to frequent loss of PTEN in prostate cancer cells may leave the oncogenic activities of Runx2 unchecked, thereby driving promiscuous expression of Runx2 target genes involved in cell migration and invasion and favoring prostate cancer progression. Cancer Res; 71(9); 3257–67. ©2011 AACR.
Elastic Modulus Determination of Normal and Glaucomatous Human Trabecular Meshwork
Last, Julie A., Pan, Tingrui , Ding, Yuzhe, Reilly, Christopher M. , Keller, Kate E. , Acott, Ted S. , Fautsch, Michael P. , Murphy, Christopher J., Russell, Paul

Mayo Clinic

Investigative Opthalmology & Visual Science | January 11, 2011 | Volume: 52 | Issue: 5 | Pages: 2147

10.1167/iovs.10-6342 | PMID 21220561 Get It

Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis
White, Thomas A. , Johnson, Tucker F. , Zarzhevsky, Natalia, Tom, Cindy W., Delacroix, Sinny , Holroyd, Eric, Maroney, Susan A. , Singh, Ripudamanjit, Pan, Shuchong, Fay, William P. , Deursen, Jan van, Mast, Alan E. , Sandhu, Gurpreet S. , Simari, Robert D.

Mayo Clinic

Blood | June 2, 2010 | Volume: 116 | Issue: 10 | Pages: 1787-1794

10.1182/blood-2009-10-250910 | PMID 20516367 Get It

AbstractThe antithrombotic surface of endothelium is regulated in a coordinated manner. Tissue factor pathway inhibitor (TFPI) localized at the endothelial cell surface regulates the production of FXa by inhibiting the TF/VIIa complex. Systemic homozygotic deletion of the first Kunitz (K1) domain of TFPI results in intrauterine lethality in mice. Here we define the cellular sources of TFPI and their role in development, hemostasis, and thrombosis using TFPI conditional knockout mice. We used a Cre-lox strategy and generated mice with a floxed exon 4 (TFPIFlox) which encodes for the TFPI-K1 domain. Mice bred into Tie2-Cre and LysM-Cre lines to delete TFPI-K1 in endothelial (TFPITie2) and myelomonocytic (TFPILysM) cells resulted in viable and fertile offspring. Plasma TFPI activity was reduced in the TFPITie2 (71% ± 0.9%, P < .001) and TFPILysM (19% ± 0.6%, P < .001) compared with TFPIFlox littermate controls. Tail and cuticle bleeding were unaffected. However, TFPITie2 mice but not TFPILysM mice had increased ferric chloride–induced arterial thrombosis. Taken together, the data reveal distinct roles for endothelial- and myelomonocytic-derived TFPI.
A preliminary study of few-view image reconstruction of sparse objects in cone-beam micro-CT
Han, Xiao , Bian, Junguo, Eaker, Diane R., Ritman, Erik L., Sidky, Emil Y. , Pan, Xiaochuan

Mayo Clinic

SPIE Proceedings | March 19, 2010 | Volume: 7622 | Issue: No issue available | Pages: 76222P

10.1117/12.845320 Get It

The Snf1-related kinase, Hunk, is essential for mammary tumor metastasis
Wertheim, Gerald , Yang, Thomas, Ramne, Anna, Liu, Zhandong , Gardner, Heather Perry, Dugan, Katherine D., Kristel, Petra, Kreike, Bas , Vijver, Marc J. van de , Cardiff, Robert D. , Reynolds, Carol, Pan, Tien-Chi , Chodosh, Lewis A.

Mayo Clinic

Proceedings of the National Academy of Sciences | August 28, 2009 | Volume: 106 | Issue: 37 | Pages: 15855-15860

10.1073/pnas.0906993106 | PMID 19717424 Get It

We previously identified a SNF1/AMPK-related protein kinase, Hunk, from a mammary tumor arising in an MMTV-neu transgenic mouse. The function of this kinase is unknown. Using targeted deletion in mice, we now demonstrate that Hunk is required for the metastasis of c-myc-induced mammary tumors, but is dispensable for normal development. Reconstitution experiments revealed that Hunk is sufficient to restore the metastatic potential of Hunk-deficient tumor cells, as well as defects in migration and invasion, and does so in a manner that requires its kinase activity. Consistent with a role for this kinase in the progression of human cancers, the human homologue of Hunk is overexpressed in aggressive subsets of carcinomas of the ovary, colon, and breast. In addition, a murine gene expression signature that distinguishes Hunk-wild type from Hunk-deficient mammary tumors predicts clinical outcome in women with breast cancer in a manner consistent with the pro-metastatic function of Hunk in mice. These findings identify a direct role for Hunk kinase activity in metastasis and establish an in vivo function for this kinase.
Vascular-Directed Tissue Factor Pathway Inhibitor Overexpression Regulates Plasma Cholesterol and Reduces Atherosclerotic Plaque Development
Pan, Shuchong, White, Thomas A. , Witt, Tyra A. , Chiriac, Anca , Mueske, Cheri S., Simari, Robert D.

Mayo Clinic

Circulation Research | August 28, 2009 | Volume: 105 | Issue: 7 | Pages: 713-720

10.1161/circresaha.109.195016 | PMID 19713537 Get It

Rationale: Tissue factor pathway inhibitor (TFPI) is a potent regulator of the tissue factor pathway and is found in plasma in association with lipoproteins. Objective: To determine the role of TFPI in the development of atherosclerosis, we bred mice which overexpress TFPI into the apolipoprotein E–deficient (apoE −/− ) background. Methods and Results: On a high-fat diet, smooth muscle 22α (SM22α)-TFPI/apoE −/− mice were shown to have less aortic plaque burden compared to apoE −/− mice. Unexpectedly, SM22α-TFPI/apoE −/− had lower plasma cholesterol levels compared to apoE −/− mice. Furthermore, SM22α-TFPI mice fed a high-fat diet had lower cholesterol levels than did wild-type mice. Because TFPI is associated with lipoproteins and its carboxyl terminus (TFPIct) has been shown to be a ligand for the very-low-density lipoprotein (VLDL) receptor, we hypothesized that TFPI overexpression may regulate lipoprotein distribution. We quantified VLDL binding and uptake in vitro in mouse aortic smooth muscle cells from SM22α-TFPI and wild-type mice. Mouse aortic smooth muscle cells from SM22α-TFPI mice demonstrated higher VLDL binding and internalization compared to those from wild-type mice. Because SM22α-TFPI mice have increased circulating levels of TFPI antigen, we examined whether TFPIct may act to alter lipoprotein distribution. In vitro, TFPIct increased VLDL binding, uptake, and degradation in murine embryonic fibroblasts. Furthermore, this effect was blocked by heparinase treatment. In vivo, systemic administration of TFPIct reduced plasma cholesterol levels in apoE −/− mice. Conclusions: These studies suggest that overexpression of TFPI lowers plasma cholesterol through the interaction of its carboxyl terminus with lipoproteins and heparan sulfate proteoglycans.
Tissue Factor Pathway Inhibitor Overexpression Inhibits Hypoxia-Induced Pulmonary Hypertension
White, Thomas A. , Witt, Tyra A. , Pan, Shuchong, Mueske, Cheryl S., Kleppe, Laurel S., Holroyd, Eric, Champion, Hunter C., Simari, Robert D.

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | July 31, 2009 | Volume: 43 | Issue: 1 | Pages: 35-45

10.1165/rcmb.2009-0144oc | PMID 19648471 Get It

Abstract Pulmonary hypertension (PH) is a commonly recognized complication of chronic respiratory disease. Enhanced vasoconstriction, pulmonary vascular remodeling, and in situ thrombosis contribute to the increased pulmonary vascular resistance observed in PH associated with hypoxic lung disease. The tissue factor pathway regulates fibrin deposition in response to acute and chronic vascular injury. We hypothesized that inhibition of the tissue factor pathway would result in attenuation of pathophysiologic parameters typically associated with hypoxia-induced PH. We tested this hypothesis using a chronic hypoxia–induced murine model of PH using mice that overexpress tissue factor pathway inhibitor (TFPI) via the smooth muscle–specific promoter SM22 (TFPISM22). TFPISM22 mice have increased pulmonary TFPI expression compared with wild-type (WT) mice. In WT mice, exposure to chronic hypoxia (28 d at 10% O2) resulted in increased systolic right ventricular and mean pulmonary arterial pressures, changes that were significantly reduced in TFPISM22 mice. Chronic hypoxia also resulted in significant pulmonary vascular muscularization in WT mice, which was significantly reduced in TFPISM22 mice. Given the pleiotropic effects of TFPI, autocrine and paracrine mechanisms for these hemodynamic effects were considered. TFPISM22 mice had less pulmonary fibrin deposition than WT mice at 3 days after exposure to hypoxia, which is consistent with the antithrombotic effects of TFPI. Additionally, TFPISM22 mice had a significant reduction in the number of proliferating (proliferating cell nuclear antigen positive) pulmonary vascular smooth muscle cells compared with WT mice, which is consistent with in vitro findings. These findings demonstrate that overexpression of TFPI results in improved hemodynamic performance and reduced pulmonary vascular remodeling in a murine model of hypoxia-induced PH. This improvement is in part due to the autocrine and paracrine effects of TFPI overexpression.
Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide
Pan, Shuchong, Chen, Horng H. , Dickey, Deborah M., Boerrigter, Guido, Lee, Candace, Kleppe, Laurel S., Redfield, Margaret M. , Potter, Lincoln R. , Burnett, John C. , Simari, Robert D., Lee, Candace Y.W., Hall, Jennifer L. , Lerman, Amir

Mayo Clinic

Proceedings of the National Academy of Sciences | June 18, 2009 | Volume: 106 | Issue: 27 | Pages: 11282-11287

10.1073/pnas.0811851106 | PMID 19541613 Get It

Alternative RNA splicing may provide unique opportunities to identify drug targets and therapeutics. We identified an alternative spliced transcript for B-type natriuretic peptide (BNP) resulting from intronic retention. This transcript is present in failing human hearts and is reduced following mechanical unloading. The intron-retained transcript would generate a unique 34 amino acid (aa) carboxyl terminus while maintaining the remaining structure of native BNP. We generated antisera to this carboxyl terminus and identified immunoreactivity in failing human heart tissue. The alternatively spliced peptide (ASBNP) was synthesized and unlike BNP, failed to stimulate cGMP in vascular cells or vasorelax preconstricted arterial rings. This suggests that ASBNP may lack the dose-limiting effects of recombinant BNP. Given structural considerations, a carboxyl-terminal truncated form of ASBNP was generated (ASBNP.1) and was determined to retain the ability of BNP to stimulate cGMP in canine glomerular isolates and cultured human mesangial cells but lacked similar effects in vascular cells. In a canine-pacing model of heart failure, systemic infusion of ASBNP.1 did not alter mean arterial pressure but increased the glomerular filtration rate (GFR), suppressed plasma renin and angiotensin, while inducing natriuresis and diuresis. Consistent with its distinct in vivo effects, the activity of ASBNP.1 may not be explained through binding and activation of NPR-A or NPR-B. Thus, the biodesigner peptide ASBNP.1 enhances GFR associated with heart failure while lacking the vasoactive properties of BNP. These findings demonstrate that peptides with unique properties may be designed based on products of alternatively splicing.
Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity
Yamoutpour, Farnaz, Bodempudi, Vidya, Park, Shay E., Pan, Weihong , Mauzy, Mary Jean, Kratzke, Robert A. , Dudek, Arkadiusz Z. , Potter, David A. , Woo, Richard A., O’Rourke, Donald M. , Tindall, Donald J., Farassati, Faris , Potter, David A , Dudek, Arkadiusz Z

Mayo Clinic

Molecular Cancer Therapeutics | November 11, 2008 | Volume: 7 | Issue: 11 | Pages: 3586-3597

10.1158/1535-7163.mct-08-0653 | PMID 19001441 Get It

Abstract Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively active mutant form of EGFR that is expressed in 40% to 50% of gliomas and several other malignancies. Here, we describe the therapeutic effects of silencing EGFRvIII on glioma cell lines in vitro and in vivo. A small interfering RNA molecule against EGFRvIII was introduced into EGFRvIII-expressing glioma cells (U87Δ) by electroporation resulting in complete inhibition of expression of EGFRvIII as early as 48 h post-treatment. During EGFRvIII silencing, a decrease in the proliferation and invasiveness of U87Δ cells was accompanied by an increase in apoptosis (P &lt; 0.05). Notably, EGFRvIII silencing inhibited the signal transduction machinery downstream of EGFRvIII as evidenced by decreases in the activated levels of Ras and extracellular signal-regulated kinase. A lentivirus capable of expressing anti-EGFRvIII short hairpin RNA was also able to achieve progressive silencing of EGFRvIII in U87Δ cells in addition to inhibiting cell proliferation, invasiveness, and colony formation in a significant manner (P &lt; 0.05). Silencing EGFRvIII in U87Δ cultures with this virus reduced the expression of factors involved in epithelial-mesenchymal transition including N-cadherin, β-catenin, Snail, Slug, and paxillin but not E-cadherin. The anti-EGFRvIII lentivirus also affected the cell cycle progression of U87Δ cells with a decrease in G1 and increase in S and G2 fractions. In an in vivo model, tumor growth was completely inhibited in severe combined immunodeficient mice (n = 10) injected s.c. with U87Δ cells treated with the anti-EGFRvIII lentivirus (P = 0.005). We conclude that gene specific silencing of EGFRvIII is a promising strategy for treating cancers that contain this mutated receptor. [Mol Cancer Ther 2008;7(11):3586–97]